



Published in final edited form as:

Cancer Res. 2009 May 15; 69(10): 4116–4124. doi:10.1158/0008-5472.CAN-08-3441.

Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics

Bryan T. Hennessy^{1,2,6}, Ana-Maria Gonzalez-Angulo^{2,3,6}, Katherine Stemke-Hale^{2,6}, Michael Z. Gilcrease⁴, Savitri Krishnamurthy⁴, Ju-Seog Lee², Jane Fridlyand⁷, Aysegül Sahin⁴, Roshan Agarwal², Corwin Joy⁵, Wenbin Liu⁵, David Stivers⁵, Keith Baggerly⁵, Mark Carey^{2,6}, Ana Lluch⁸, Carlos Monteagudo⁹, Xiaping He¹⁰, Victor Weigman¹⁰, Cheng Fan¹⁰, Juan Palazzo¹¹, Gabriel N. Hortobagyi³, Laura K. Nolden², Nicholas J. Wang⁷, Vicente Valero³, Joe W. Gray⁷, Charles M. Perou¹⁰, and Gordon B. Mills^{2,6}

¹Department of Gynecologic Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

²Department of Systems Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

³Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

⁴Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

⁵Department of Bioinformatics and Computational Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

⁶Department of Kleberg Center for Molecular Markers, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

⁷Lawrence Berkeley National Laboratory, Berkeley, California

⁸Clinic Hospital, Valencia, Spain

⁹University of Valencia, Valencia, Spain

¹⁰Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

¹¹Department of Pathology, Thomas Jefferson University, Philadelphia, Pennsylvania

Abstract

Metaplastic breast cancers (MBC) are aggressive, chemoresistant tumors characterized by lineage plasticity. To advance understanding of their pathogenesis and relatedness to other breast cancer subtypes, 28 MBCs were compared with common breast cancers using comparative genomic hybridization, transcriptional profiling, and reverse-phase protein arrays and by sequencing for

© 2009 American Association for Cancer Research

Requests for reprints: Bryan T. Hennessy, Department of Gynecologic Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-563-1792; Fax: 713-745-1541; E-mail: bhennessy@mdanderson.org.

B.T. Hennessy and A-M. Gonzalez-Angulo are co-first authors. C.M. Perou and G.B. Mills are co-senior authors.

Note: Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

common breast cancer mutations. MBCs showed unique DNA copy number aberrations compared with common breast cancers. *PIK3CA* mutations were detected in 9 of 19 MBCs (47.4%) versus 80 of 232 hormone receptor–positive cancers (34.5%; $P = 0.32$), 17 of 75 *HER-2*–positive samples (22.7%; $P = 0.04$), 20 of 240 basal-like cancers (8.3%; $P < 0.0001$), and 0 of 14 claudin-low tumors ($P = 0.004$). Of 7 phosphatidylinositol 3-kinase/AKT pathway phosphorylation sites, 6 were more highly phosphorylated in MBCs than in other breast tumor subtypes. The majority of MBCs displayed mRNA profiles different from those of the most common, including basal-like cancers. By transcriptional profiling, MBCs and the recently identified claudin-low breast cancer subset constitute related receptor-negative subgroups characterized by low expression of GATA3-regulated genes and of genes responsible for cell-cell adhesion with enrichment for markers linked to stem cell function and epithelial-to-mesenchymal transition (EMT). In contrast to other breast cancers, claudin-low tumors and most MBCs showed a significant similarity to a “tumorigenic” signature defined using CD44⁺/CD24[−] breast tumor–initiating stem cell–like cells. MBCs and claudin-low tumors are thus enriched in EMT and stem cell–like features, and may arise from an earlier, more chemoresistant breast epithelial precursor than basal-like or luminal cancers. *PIK3CA* mutations, EMT, and stem cell-like characteristics likely contribute to the poor outcomes of MBC and suggest novel therapeutic targets.

Introduction

Metaplastic breast cancers (MBC) are aggressive estrogen receptor- α -negative, progesterone receptor-negative, *HER-2*-negative (triple-negative) tumors characterized by mesenchymal/sarcomatoid and/or squamous metaplasia of malignant breast epithelium (1–7). Because of limited understanding of their pathogenesis, MBCs are treated in the same fashion as basal-like or triple receptor-negative ductal cancers. However, whereas neoadjuvant chemotherapy is associated with high pathologic complete response rates in basal-like carcinomas, MBCs are usually chemoresistant (2).

Transcriptional profiling has defined breast cancer subtypes (8,9). The origin of luminal A and B tumors appears to be the mammary duct luminal epithelium with concomitant hormone receptor expression. Elevated *HER-2* expression defines a subgroup with a poor prognosis; however, the responsiveness of this subgroup to trastuzumab improves outcomes (10). In contrast, basal-like cancers likely represent multiple different subtypes arising from distinct precursor cells from those of other cancers. Some basal-like breast cancers likely arise from mammary myoepithelial cells. To date, basal-like cancers have not presented specific therapy targets.

As MBCs are triple-negative, they are distinct from luminal and *HER-2*-amplified cancers. As they express some markers associated with basal-like cancers (e.g., epidermal growth factor receptor and cytokeratins 5/6), MBCs are proposed to represent a form of basal-like breast cancer. However, distinct clinical features such as chemoresistance suggest that MBCs may represent a unique subtype (2,3).

We applied an integrated genomic-proteomic approach to determine mechanisms underlying metaplastic carcinogenesis and MBC chemoresistance along with the relatedness of MBCs to known breast cancer subtypes. Most MBCs showed a unique molecular profile and form a distinct subtype most closely related to a novel subset of receptor-negative breast cancers (claudin-low) characterized by loss of genes involved in cell-cell adhesion. An enrichment for stem cell-like and epithelial-to-mesenchymal transition (EMT) markers in MBCs (and claudin-low tumors) along with frequent genomic aberrations that activate the phosphatidylinositol 3-kinase (PI3K)/AKT pathway suggest reasons for MBC chemoresistance and that MBCs and claudin-low tumors may arise from more immature precursor cells than other breast cancers.

Materials and Methods

Human tumors

Twenty-eight frozen grade 3 MBCs with sarcomatoid (19) or squamous (9) metaplasia were obtained from the Breast Tumor Bank at The University of Texas M. D. Anderson Cancer Center (MDACC) and from a collaborator in Valencia (A.L.). The diagnosis was reconfirmed by pathologists at MDACC (M.Z.G. and S.K.; refs. 2,3). Frozen tissue was used for DNA extraction (28 tumors) and, where adequate frozen tumor tissue remained, for RNA and protein extraction (16 MDACC tumors; ref. 11).

Three tumor cohorts were used for comparison with MBCs (Supplementary Fig. S1). The first cohort, used for comparison of mutation frequency (547 tumors) and functional proteomic profiles (693), was composed of 693 frozen primary breast tumors obtained under institutional review board-approved protocols from MDACC. These tumors were subdivided into clinically defined subtypes as described previously (Table 1; ref. 12).

A second cohort of 145 primary breast tumors was used for comparison with MBC gene copy number profiles herein (13,14). A third cohort (Lineberger Comprehensive Cancer Center) of 184 breast tumors and 9 normal breast tissues was used for comparison with MBC transcriptional profiles (8,9,15). There were no statistically significant differences in the proportion of patients with tumors of different stages between the cohorts.

Comparative genomic hybridization

Comparative genomic hybridization profiles from the 28 MBCs were generated at Lawrence Berkeley National Laboratory using single nucleotide polymorphism (SNP)-based GeneChip Human Mapping 50K Sty arrays (Affymetrix) and compared with BAC-comparative genomic hybridization profiles of primary breast tumors previously generated and processed (J.F.) at Lawrence Berkeley National Laboratory using HumArray1.14/HumArray2.0 (13,14,16–18). MBC 50K data are available.¹²

For comparison with Lawrence Berkeley National Laboratory tumors, the 28 MBC SNP chips were mapped to BAC resolution. This approach has been validated by comparing data derived using both platforms to analyze breast cancer cell lines (data not shown). Lawrence Berkeley National Laboratory tumors were remapped to the May04 freeze from University of California-Santa Cruz and regions around each BAC clone were defined as within a half distance to each neighboring clone or to the beginning or end of the chromosome if telomeric. A median expression value was then obtained for SNPs in each BAC region. Missing values were assigned if <5 SNPs mapped to a particular region. Each array was recentered to have a median of 0. The resulting values were segmented using circular binary segmentation (CBS) followed by a merge-level procedure to combine segmented levels across the genome. Each missing value was assigned the value of its corresponding segment. Gain/loss events and fraction of genome altered were calculated. After this resolution reduction (median, 18 SNPs/BAC; mean, 30), the mean variability estimate was 0.25. Similar analyses beginning with the CBS steps were done on the original dChip processed data. We used a Fisher's test to measure the difference in copy number at probes on each side of genes encoding PI3K/AKT pathway components. These *P* values were used to fit a β -uniform mixture model to determine significance at a given false discovery rate.

¹²<ftp://beamish.lbl.gov/njwang/>

To directly compare the 50K SNP and older BAC platforms, DNA extracted from five MBCs was also run using the BAC platform. This confirmed a high concordance for the matched data derived from the two platforms (data not shown).

Detection of mutations

DNA was extracted from 547 MDACC breast tumors along with 14 Lineberger Comprehensive Cancer Center claudin-low breast tumors and 19 MBCs with sufficient remaining DNA for mutation detection (9,11,12). Following whole-genome amplification, *p53/PTEN* genes were resequenced (19). *CTNNB1* exon 3 (the most common site of mutations) was amplified from genomic DNA using a forward primer located at the 5' portion and a reverse primer at the 3' end of the exon. A tumor sample with a known *CTNNB1* mutation was amplified and sequenced in parallel with tumor samples as a positive control. A SNP-based approach (Sequenom MassArray) was used to detect mutations in *PIK3CA*, *KRAS*, and E17K mutations in the *AKT1/2/3* genes (12,20). This approach is unsuitable for detection of mutations that are not "hotspot" mutations but is particularly suitable to mutation detection in breast cancer where stromal "contamination" is prevalent (21).

Reverse-phase protein array

Reverse-phase protein array was applied with the antibodies in Supplementary Table S1 to compare PI3K/AKT and mitogen-activated protein kinase (MAPK) pathway activation in protein lysates derived from 16 MBCs versus 693 common breast cancers (Supplementary Table S2; refs. 22–25). The expression of each antibody in a sample was corrected for protein loading using the average expression levels of all probed proteins. Antibodies were obtained from SDI (YB1), Epitomics, Inc. (p70S6K, PR), Lab Vision Corporation ($ER\alpha$), Santa Cruz Biotechnology (CCND1, CCNE1, EGFR, GSK3, p27), Upstate Biotechnology (Src) and Cell Signaling Technology, Inc.

Transcriptional profiling

Total RNA was isolated by phenol-chloroform extraction (Trizol, Life Technologies), and mRNA was purified by either magnetic separation using Dynabeads (Dyna) or the Invitrogen FastTrack 2.0 Kit. Twelve of 16 MBC RNA samples with RNA integrity numbers > 6 were assayed on Agilent oligomicroarrays at Lineberger Comprehensive Cancer Center and compared with a published Agilent microarray data set also previously assayed and processed (C.M.P.) at Lineberger Comprehensive Cancer Center (8,9,15). The microarray and clinical data are available at University of North Carolina Microarray Database and in the Gene Expression Omnibus (GSE10885). Expression Analysis Systematic Explorer was applied to perform functional analysis of gene lists.

Mapping gene expression onto regions of MBC copy number change

Using a Significance Analysis of Microarray (SAM)-defined list of MBC-defining genes, we determined the chromosomal location of each gene to link with the comparative genomic hybridization data. Probes with an undefined chromosomal position were discarded from further analyses. CBS was applied to the preprocessed MBC copy number data to determine breakpoints for aberrations (26). The CBS calls made were as follows: `class.segment <- segment(class.cna, α = 0.05, p.method = "perm," nperm = 1,000, trim = 0.05, undo.splits = "sdundo," undo.SD = 2, verbose = 2)`. Using CBS output, a plot of segment intensities versus segment markers was used to determine an intensity boundary threshold of 0.12. Segments with intensity values beyond this threshold were flagged as gained or lost based on the sign of intensity and parsed from the original CBS output. By applying a customized R script to this output, segments from each sample were collated and regions were assigned that had varying levels of overlap between the MBC patients. Cutoffs were made for regions with aberrations

in ≥ 1 of 3 of MBCs tested. SAM genes with chromosomal locations that were contained within these gains and losses were determined and plotted.

Comparison of the MBC and claudin-low transcriptional profiles with a CD44⁺/CD24^{-low} breast cancer cell profile

We compared breast tumor transcriptional signatures with a “tumorigenic” signature¹³ that was derived by comparing gene expression profiles of flow-sorted CD44⁺/CD24^{-low} cancer cells with profiles of all other sorted cells (CD44⁻/CD24⁺ and CD44⁻/CD24⁻ combined). For each tumor, a “R value” was derived in relation to the “tumorigenic” signature, which was defined as the Pearson’s correlation between the “tumorigenic” gene signature pattern (using “1” and “-1” for up and down, respectively) and tumor expression values. Tumors with high R values would tend to have both high expression of many of the genes high in “tumorigenic” cells and low expression of many of the genes low in “tumorigenic” cells (and vice versa for tumors with low R values).

Statistical analysis

R¹⁴ and NCSS/PASS software were used. Reported *P* values are two sided. ANOVA and *t* tests for gene expression data were done using SAS. For clustering, we used CLUSTER and TREEVIEW (University of Glasgow) softwares.

Results

MBCs possess patterns of DNA copy number gains and losses that are distinct from those in common breast cancers

MBCs showed a high level of genomic instability based on fraction of the genome altered and number of transitions. However, MBCs showed a unique set of aberrations compared with common breast cancers (Fig. 1; refs. 13,14). Specifically, gains of distal chromosome 1p/5p and loss of 3q were common in MBCs but rare in other breast cancers (13,14). Conversely, alterations that occur in most breast cancers, such as gain of chromosome 1q and loss of 16q, were uncommon in MBC (13,14). In particular, compared with basal-like tumors, MBCs exhibited more frequent amplification of 1p/11q/12q/14q/19p/19q/22q and increased frequency of loss at 1q/2p/3q/8q. There was retention of 5q/9q/15q/16p/17p/17q/19p/19q/20q/22q compared with basal-like tumors. Overall, MBCs did not display similar alterations to basal-like cancers and showed substantial differences from common breast cancers, compatible with MBCs representing a distinct subgroup.

MBCs possess distinct patterns of somatic mutations from basal-like breast cancers

PIK3CA mutations were detected in 9 of 19 (47.4%) MBCs compared with 80 of 232 (34.5%) hormone receptor-positive cancers (*P* = 0.32), 17 of 75 (22.7%) *HER-2*-amplified samples (*P* = 0.04), 20 of 240 (8.3%) triple-negative cancers (*P* < 0.0001), and 0 of 14 claudin-low tumors (*P* = 0.004; Table 1; ref. 12). The *PIK3CA* mutation frequencies in the common subtypes are compatible with those frequencies reported in the literature, with the exception of that in claudin-low tumors, which has not been reported (27). One *PTEN* mutation was detected in a MBC (5%) that did not have a *PIK3CA* mutation. *p53* mutations were detected in 6 of 19 (32%) MBCs. No mutation in exon 3 of *CTNNB1* was detected in 19 MBCs.

Strikingly, therefore, 10 of 19 (53%) MBCs showed PI3K/AKT pathway mutations. This was significantly different from the mutation rate in triple-negative/basal-like cancers in particular.

¹³Creighton et al., submitted for publication.

¹⁴<http://cran.r-project.org>

Further, other PI3K/AKT pathway genomic aberrations were more frequent in MBCs. Based on two SNP probes closest to each end of genes encoding PI3K/AKT components, *AKT1* (chromosome 14), *AKT2* (chromosome 19), and *RPS6KB2* (p70S6K, chromosome 11) showed more frequent copy number gain (Fisher's exact test, $P < 0.05$ at a 1% false discovery rate) in MBCs compared with other subtypes. This was also supported at the protein level using reverse-phase protein array data (Supplementary Table S2). Thus, PI3K/AKT pathway aberrations likely play a major role in MBC pathophysiology, further suggesting that MBCs and basal-like tumors are distinct.

PI3K pathway activation in MBC

The high frequency of genomic aberrations in PI3K/AKT pathway genes implicates this pathway in MBC pathogenesis. This pathway has already been implicated in breast cancer resistance to multiple therapies (28–30). Using reverse-phase protein array, phosphorylation of most core PI3K/AKT pathway proteins was elevated in MBCs compared with at least one other breast tumor subtype (Fig. 2), with the exception of phosphorylated p70S6K. The most likely explanation for the latter discrepancy is phosphorylation of p70S6K by kinases other than core PI3K/AKT pathway kinases (31,32). Overall, however, key PI3K/AKT pathway components are generally more highly phosphorylated in MBCs than in most other breast tumors, which parallels the results of the genomic analyses and could contribute to the poor outcomes associated with MBC (Supplementary Fig. S2).

Only glycogen synthase kinase 3 phosphorylation was higher in MBCs possessing mutant versus wild-type *PIK3CA/PTEN* genes ($P = 0.01$). The failure to show an association between PI3K/AKT pathway mutations and activation is potentially due to the small number of tumors analyzed. However, alterations in PI3K/AKT pathway activation by processes independent of mutations, by other interacting pathways, or by signaling modulation through feedback loops may have prevented identification of statistically significant associations (33). Compatible with the latter contention, we have shown previously that *PIK3CA* mutational status is not correlated with AKT phosphorylation in hormone receptor-positive breast cancers or cell lines (12).

We also quantified expression and phosphorylation of several PI3K/AKT pathway-activating and pathway-related proteins (Supplementary Table S2). Epidermal growth factor receptor expression was lower in MBCs compared with other breast cancer subtypes. HER-2 levels were also significantly decreased in MBCs relative to hormone receptor-positive, triple-negative, and, in particular, HER-2-positive tumors. Cyclin E1, a PI3K/AKT pathway target, was present at higher levels in MBCs compared with hormone receptor-positive and HER-2-positive tumors ($P = 0.0005$ and 0.02 , respectively; refs. 34,35). The Y box-binding protein 1 (YB1) has been implicated in chemoresistance and is located in the chromosome 1p amplicon in MBC (Fig. 1; ref. 36). Indeed, *YB1* was more frequently amplified (at 1% false discovery rate) in MBCs than in other tumors, and YB1 protein expression was also higher in MBCs.

MBC transcriptional profiles are distinct from those of basal-like breast cancers and related to those of claudin-low breast tumors

On unsupervised hierarchical clustering, the majority of MBCs displayed markedly different mRNA profiles from those of most common breast cancers including basal-like cancers (data not shown). To explore the relationships between MBCs and the intrinsic breast cancer subtypes, 12 MDACC MBCs were compared with 184 breast tumors and 9 normal breast samples by hierarchical clustering using a combination of four intrinsic gene lists (8,9,15,37). MBCs were somewhat heterogeneous in this analysis (Supplementary Fig. S3). Two MBCs clustered with basal-like tumors, two with a novel subtype of receptor-negative tumors that is characterized by loss of a cluster of genes that encode proteins involved in cell-cell adhesion (claudin-low tumors), two clustered within the normal-like group, and six formed a novel

subgroup with characteristics intermediate between those of basal-like and claudin-low tumors (Supplementary Fig. S3).

To assess the significance of this clustering pattern, we applied “SigClust” to test the null hypothesis that any group of samples contained within a common dendrogram branch constitutes a single group (38). This analysis showed that the dendrogram branch containing six MBCs, along with some previously assayed tumors, represents a distinct group. On reanalysis of the histology of the latter tumors, four showed metaplastic and/or spindle features compatible with the tumors representing MBCs (Supplementary Fig. S4). Further, mouse mammary tumors that are similar to human claudin-low tumors show a spindle morphology (9).

The gene set that defines claudin-low and MBC tumors (Supplementary Fig. S3C) was determined by Gene Ontology analysis to be enriched for the terms tight junction, intercellular junction, apicolateral plasma membrane, and cell junction. Of 29 claudin-low cluster genes, 13 are positively regulated by GATA3 and none by estrogen receptor- α (hypergeometric mean analysis, $P < 0.01$; ref. 39). In addition to lacking genes involved in cell-cell adhesion and polarity, MBCs and claudin-low tumors lack luminal genes including GATA3 (Supplementary Fig. S3F) and HER-2 and show inconsistent expression of genes associated with basal-like tumors (Supplementary Fig. S3D). *t* tests confirmed that the expression of the claudin-low cluster of genes (Supplementary Fig. S3C) was lower in MBCs versus other breast cancers (Supplementary Table S3).

MBCs and claudin-low tumors express high levels of stem cell and EMT markers

SAM was used to identify a MBC versus common breast tumor expression signature (40,41). This analysis resulted in 556 up and 373 down genes, with a false discovery rate of <1 gene (Supplementary Table S4). Almost 33% of the “SAM up” and 50% of the SAM down genes mapped to regions of copy number aberration (see below). In a Gene Ontology analysis using Expression Analysis Systematic Explorer, the top six enriched biological processes in the “up” gene list were cell communication, cell adhesion, signal transduction, cellular process, cell-cell adhesion, and intracellular protein transport, whereas protein transport, intracellular transport, transport, male meiosis, and ubiquitin-dependent protein catabolism were enriched in the “down” gene list (40). The claudin-low gene cluster showed a statistically significant overlap with the SAM-defined “down” genes (15 of 29 genes; hypergeometric mean analysis, $P < 0.001$). Genes near the top of the MBC “up” list that have been previously implicated in carcinogenesis included ALK, crystallin γ , and the master regulator of EMT, TWIST1 (42–45).

Breast cancers are thought to contain a minority population of tumor initiating/stem cell-like cells with high CD44 but low or undetectable levels of CD24 (CD44⁺/CD24⁻); these cells have higher “tumorigenic” capacity than other purified populations of tumor-derived cells (46). Their phenotype and the low responsiveness of MBCs to chemotherapy suggest that MBCs might possess stem cell-like characteristics. Indeed, MBCs had markedly elevated CD44/CD24 and CD29/CD24 ratios compared with other breast cancers, with the exception of claudin-low tumors (Fig. 3). This “electronic stem cell signature” is also differentially expressed between fluorescence-activated cell-sorted human breast tumor-initiating cells and normal breast epithelial cells (Supplementary Fig. S5; refs. 46,47).

EMT is characterized by the up-regulation of vimentin and of E-cadherin repressor molecules (snail/slug/twist) with down-regulation of E-cadherin and other cell adhesion molecules (45, 48,49). These events occur in MBCs and claudin-low tumors (Fig. 3; Supplementary Table S3). In MBCs, TWIST1 and snail homologue 2 (SNAI2/SLUG) were expressed at high levels, whereas SNAI3 was overexpressed in claudin-low tumors. Thus, claudin-low tumors and

MBCs may be enriched for stem cell-like and EMT markers, features that may contribute to poor patient outcomes (Supplementary Fig. S2; refs. 2,3).

Genes that are altered at the genomic and transcriptional levels in MBC

Three hundred six genes (Supplementary Table S5) in the SAM-derived MBC transcriptome localized to areas of chromosomal gain and loss in at least 33% of MBCs (Supplementary Fig. S6A and B). Thus, these genes show coordinate changes at the DNA and RNA levels in MBC. Functional analysis of these genes (Supplementary Tables S6 and S7) showed that, among genes that are amplified and overexpressed in MBCs, components of three major branches (JNK, MAPK, and p38) that compose the MAPK signaling pathway are significantly overrepresented in MBCs. Compatible with this finding, phosphorylation of three of four assessed protein components of these pathways [JNK ($P = 0.06$), MEK ($P = 0.003$), and p38 ($P = 0.0008$) but not ERK1/2 ($P = \text{NS}$)] was higher in MBCs versus all other breast cancers.

Comparison of the MBC and claudin-low transcriptional profiles with a CD44⁺/CD24^{-low} breast cancer cell profile

Given their enrichment for stem cell markers, we compared the transcriptional signatures of MBCs and other breast cancers with a “tumorigenic” signature¹³ that was derived by comparing gene expression profiles of flow-sorted CD44⁺/CD24^{-low} breast tumor cells with profiles of all other sorted cells (CD44⁻/CD24⁺ and CD44⁻/CD24⁻). In contrast to other breast cancers, except for tumors of the “claudin-low” subtype, most of the MBCs showed a clear association with the “tumorigenic” signature (Fig. 4). Further, of 373 and 217 down-regulated genes in the MBC and “tumorigenic” signatures, respectively, there were 29 shared genes (Supplementary Table S8; $P = 1 \times 10^{-13}$ for the overlap); 5 of these 29 genes were components of the claudin-low gene cluster. In addition, as has been shown with the claudin-low signature,¹³ the MBC signature is enriched in post-docetaxel and post-letrozole treatment specimens (Supplementary Fig. S7). These data collectively suggest that, at diagnosis, MBCs and claudin-low tumors possess transcriptional features that are enriched in highly purified breast tumor-initiating and chemoresistant breast cancer cell fractions (50), the latter also compatible with an enrichment for stem cell-like activity.

Discussion

MBCs are aggressive, chemoresistant tumors associated with poor outcomes (2,3). Although uncommon, MBCs account for several hundred new breast cancer cases every year in the United States, thus representing a therapeutic dilemma for oncologists. With only retrospective case reviews as a basis for making recommendations, it has not been possible to define therapy guidelines. Thus, we sought to determine the relationship of MBCs to common breast cancers, particularly basal-like breast cancers given the common assumption that MBCs are basal-like cancers. We also sought to determine whether the underlying pathophysiology of MBCs would result in the identification of new drug targets.

Supplementary Fig. S8 summarizes the features of MBC defined in this study that have potential clinical and therapeutic utility. Due to low expression of hormone receptors and HER-2 as well as expression of some basal epithelial markers, MBCs have been proposed to represent a form of basal-like breast cancer (4). However, based on the integrated analyses herein, most MBCs likely represent an independent subtype that is distinct from basal-like cancers. Their transcriptional profiles are most closely related to claudin-low cancers, a novel subgroup of receptor-negative breast cancers that are clearly different from basal-like cancers (Supplementary Fig. S3). Comparative genomic hybridization profiles, their enrichment for stem cell-like markers, and their PI3K/AKT pathway activation status also differentiate MBCs from basal-like cancers. MBCs, like claudin-low cancers, express high levels of EMT markers

and show elevated CD44/CD24 and CD29/CD24 ratios, which have been proposed to represent breast cancer stem cell-like markers (46). Indeed, a recent study detected a direct and causative link between EMT and the gain of epithelial stem cell properties (51). These features likely contribute to the lineage plasticity of MBCs on light microscopy and to their limited chemoresponsiveness (2,3). Claudin-low features, including EMT and stem cell-like properties, also potentially contribute to the aggressive phenotype of MBCs. This is supported by the significant overlap between the MBC signature and the “tumorigenic” signature,¹³ with overlapping genes including five of the claudin-low genes (Supplementary Fig. S3C). The MBC, the “tumorigenic,” and the claudin-low signatures are all enriched in residual post-treatment chemoresistant breast tumors. Thus, MBCs and claudin-low breast tumors may arise from a more primitive and chemoresistant “stem” cell than luminal or basal-like tumors.

The pattern of chromosomal gains and losses in MBCs is distinct from that in other breast cancers including basal-like cancers. This unique pattern suggests that the processes underlying metaplastic carcinogenesis are distinct from those associated with other breast cancer subtypes. MBCs show a high frequency of mutation, amplification, and activation of PI3K/AKT pathway components. This is markedly different from basal-like breast cancers, where we and others have shown that PI3K/AKT pathway genomic mutations are uncommon (12,27).¹⁵ We also did not detect *PIK3CA* mutations in 14 claudin-low breast cancers pointing to differences between claudin-low breast cancers and MBCs. The frequency of *PIK3CA* and *PTEN* mutations combined with amplification of *AKT* and *p70S6K* suggests that PI3K/AKT pathway activation is critical to metaplastic carcinogenesis. Activation of this pathway, along with enrichment for tumor-initiating/stem cells, may underlie the chemoresistance and poor outcomes associated with MBC (28–30). MBCs also show a high frequency of amplification, overexpression, and activation of MAPK pathway components. As particularly important genes and targets in cancer are likely to be aberrant at the level of the genome, transcriptome, and proteome, the PI3K/AKT and MAPK pathways are therefore potentially attractive therapy targets in MBC. As inhibitors of the PI3K/AKT and MAPK pathways are now in clinical trials, it will be of interest to determine whether these inhibitors will sensitize MBCs to cytotoxic drugs (52). As there are no MBC cell lines or animal models available, it will be necessary to develop a consortium approach to test this hypothesis in patients.

In contrast to a recently published study, mutations in exon 3 of *CTNNB1* were not identified in 19 MBCs in our study (53). This may in part relate to the fact that our study was restricted to high-grade MBCs, whereas the previous study included a significant proportion of lower-grade MBCs, tumors that behave in a less aggressive fashion than high-grade MBCs.

This study has several potential limitations. Although a subset (6 of 12, 50%) of MBCs constitute a significantly related group of tumors as defined by SigClust, it is clear that MBCs form a somewhat heterogeneous group of receptor-negative breast cancers in terms of their molecular characteristics. Just as breast tumors that are defined as ductal are clearly heterogeneous based on receptor status and transcriptional profiling, it is not surprising that MBCs represent a molecularly heterogeneous group. MBCs are microscopically heterogeneous, with this study being limited to tumors with squamous and sarcomatoid metaplasia (1–7). The rarity of MBC precluded analysis of other histologic variants. In addition, it is possible that MBC represents multiple different diseases. However, there were no clear correlation between the pattern of gene copy number change and the histologic appearance of the tumors analyzed.

The major conclusions of this article are (a) MBCs are molecularly distinct from other breast cancers; (b) despite their relative histologic uniformity, MBCs are molecularly heterogeneous;

¹⁵www.sanger.ac.uk

and (c) claudin-low breast cancers are likely the most closely related ductal breast cancer subset to MBCs. The molecular mechanisms underlying metaplastic carcinogenesis are likely different from those associated with other breast cancer subtypes including basal-like cancers. By gene expression analysis, MBCs and claudin-low tumors share common features that suggest related cellular origins, potentially from a more primitive cell than that implicated as a precursor to luminal or basal-like tumors. It is likely that MBCs, and potentially claudin-low tumors, define a novel chemoresistant triple-negative breast cancer subgroup that exhibits a signature similar to that of breast tumor-initiating cells and of residual common breast tumor cells isolated after patient treatment. The frequency of PI3K/AKT pathway aberrations argues that this pathway should be explored as a therapeutic target in MBC. A challenge to advancing therapy for MBC patients is the infrequency of this disease. However, a centralized clinical trial effort is a feasible venture that will improve patient outcomes.

Acknowledgments

Grant support: Kleberg Center for Molecular Markers at MDACC, Cancer Center Support Grant CA16672 at MDACC, and MDACC Physician Scientist Program and The McNair Scholars Program supported by The Robert and Janice McNair Foundation (B.T. Hennessy); National Cancer Institute grants K23-CA121994 and R21-CA120248 and National Cancer Institute Breast Specialized Program for Research Excellence grant P50-CA116199 (A-M. Gonzalez-Angulo); National Cancer Institute grants CA116199 and CA099031 (G.B. Mills); Komen Foundation grant FAS0703849 (G.B. Mills, A-M. Gonzalez-Angulo, and B.T. Hennessy); National Cancer Institute Breast Specialized Program for Research Excellence grants P50-CA58223-09A1 and RO1-CA-101227-01, V Foundation for Cancer Research, and Breast Cancer Research Foundation (C.M. Perou); and Director, Office of Science, Office of Biological & Environmental Research, U.S. Department of Energy contract DE-AC02-05CH11231 and NIH/National Cancer Institute grants P50 CA58207 and U54 CA112970 (J.W. Gray).

We thank Len Pennacchio and Jan-Fang Cheng (Lawrence Berkeley National Laboratory) for Sanger sequencing and Jenny Chang and Chad Creighton for sharing data and providing analysis concerning their “tumorigenic” signature in Creighton et al. (submitted for publication).

References

1. Tavassoli, FA. Pathology of the breast. Vol. 2nd ed.. Hong Kong: Appleton and Lange; 1999. 1999
2. Hennessy BT, Giordano S, Broglio K, et al. Biphasic metaplastic sarcomatoid carcinoma of the breast. *Ann Oncol* 2006;17:605–613. [PubMed: 16469754]
3. Hennessy BT, Krishnamurthy S, Giordano S, et al. Squamous cell carcinoma of the breast. *J Clin Oncol* 2005;23:7827–7835. [PubMed: 16258085]
4. Reis-Filho JS, Milanezi F, Steele D, et al. Metaplastic breast carcinomas are basal-like tumours. *Histopathology* 2006;49:10–21. [PubMed: 16842242]
5. Wargotz ES, Deos PH, Norris HJ. Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. *Hum Pathol* 1989;20:732–740. [PubMed: 2473024]
6. Foschini MP, Dina RE, Eusebi V. Sarcomatoid neoplasms of the breast: proposed definitions for biphasic and monophasic sarcomatoid mammary carcinomas. *Semin Diagn Pathol* 1993;10:128–136. [PubMed: 8367622]
7. Gutman H, Pollock RE, Janjan NA, Johnston DA. Biologic distinctions and therapeutic implications of sarcomatoid metaplasia of epithelial carcinoma of the breast. *J Am Coll Surg* 1995;180:193–199. [PubMed: 7850054]
8. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci U S A* 2001;98:10869–10874. [PubMed: 11553815]
9. Herschkowitz JI, Simin K, Weigman VJ, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. *Genome Biol* 2007;8:R76. [PubMed: 17493263]
10. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *N Engl J Med* 2005;353:1673–1684. [PubMed: 16236738]

11. Pinkel D, Seagraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. *Nat Genet* 1998;20:207–211. [PubMed: 9771718]
12. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN and AKT mutations in breast cancer. *Cancer Res* 2008;68:6084–6091. [PubMed: 18676830]
13. Chin K, DeVries S, Fridlyand J, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. *Cancer Cell* 2006;10:529–541. [PubMed: 17157792]
14. Fridlyand J, Snijders AM, Ylstra B, et al. Breast tumor copy number aberration phenotypes and genomic instability. *BMC Cancer* 2006;6:96. [PubMed: 16620391]
15. Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. *BMC Genomics* 2006;7:96. [PubMed: 16643655]
16. Snijders AM, Schmidt BL, Fridlyand J, et al. Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma. *Oncogene* 2005;24:4232–4242. [PubMed: 15824737]
17. Snijders AM, Nowak N, Seagraves R, et al. Assembly of microarrays for genome-wide measurement of DNA copy number. *Nat Genet* 2001;29:263–264. [PubMed: 11687795]
18. Janne PA, Li C, Zhao X, et al. High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines. *Oncogene* 2004;23:2716–2726. [PubMed: 15048096]
19. Tartaglia M, Pennacchio LA, Zhao C, et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. *Nat Genet* 2007;39:75–79. [PubMed: 17143282]
20. Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene mutation profiling in human cancer. *Nat Genet* 2007;39:347–351. [PubMed: 17293865]
21. West RB, Nuyten DS, Subramanian S, et al. Determination of stromal signatures in breast carcinoma. *PLoS Biol* 2005;3:e187. [PubMed: 15869330]
22. Tibes R, Qiu Y, Lu Y, Hennessy B, Mills GB, Kornblau S. Reverse phase protein array (RPPA): validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. *Mol Cancer Ther* 2006;5:2512–2521. [PubMed: 17041095]
23. Liang J, Shao SH, Xu ZX, et al. The energy sensing LKB1-AMPK pathway regulates p27^{kip1} phosphorylation mediating the decision to enter autophagy or apoptosis. *Nat Cell Biol* 2007;9:218–224. [PubMed: 17237771]
24. Hu J, He X, Baggerly KA, Coombes KR, Hennessy BT, Mills GB. Non-parametric quantification of protein lysate arrays. *Bioinformatics* 2007;23:1986–1994. [PubMed: 17599930]
25. Hennessy BT, Lu Y, Poradosu E, et al. Quantified pathway inhibition as a pharmacodynamic marker facilitating optimal targeted therapy dosing: Proof of principle with the AKT inhibitor perifosine. *Clin Cancer Res* 2007;13:7421–7431. [PubMed: 18094426]
26. Venkatraman ES, Olshen AB. A faster circular binary segmentation algorithm for the analysis of array CGH data. *Bioinformatics* 2007;23:657–663. [PubMed: 17234643]
27. Saal LH, Holm K, Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. *Cancer Res* 2005;65:2554–2559. [PubMed: 15805248]
28. Stassi G, Garofalo M, Zerilli M, et al. PED mediates AKT-dependent chemoresistance in human breast cancer cells. *Cancer Res* 2005;65:6668–6675. [PubMed: 16061647]
29. Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. *Clin Cancer Res* 2004;10:7031–7042. [PubMed: 15501983]
30. Knuefermann C, Lu Y, Liu B, et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. *Oncogene* 2002;22:3205–3212. [PubMed: 12761490]
31. Le Pabic H, L’Helgoualc’h A, Coutant A, et al. Involvement of the serine/threonine p70S6 kinase in TGF- β 1-induced ADAM12 expression in cultured human hepatic stellate cells. *J Hepatol* 2005;43:1038–1044. [PubMed: 16139919]

32. Grove JR, Price DJ, Banerjee P, Balasubramanyam A, Ahmad MF, Avruch J. Regulation of an epitope-tagged recombinant Rsk-1 S6 kinase by phorbol ester and ERK/MAP kinase. *Biochemistry* 1993;32:7727–7738. [PubMed: 7688567]
33. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. *Oncogene* 2007;26:1932–1940. [PubMed: 17001314]
34. Lee SR, Park JH, Park EK, Chung CH, Kang SS, Bang OS. Akt-induced promotion of cell-cycle progression at G₂/M phase involves upregulation of NF- κ B binding activity in PC12 cells. *J Cell Physiol* 2005;205:270–277. [PubMed: 15887249]
35. Reichert M, Saur D, Hamacher R, Schmid RM, Schneider G. Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells. *Cancer Res* 2007;67:4149–4156. [PubMed: 17483325]
36. Huang J, Tan PH, Li KB, Matsumoto K, Tsujimoto M, Bay BH. Y-box binding protein, YB-1, as a marker of tumor aggressiveness and response to adjuvant chemotherapy in breast cancer. *Int J Oncol* 2005;26:607–613. [PubMed: 15703814]
37. Perreard L, Fan C, Quackenbush JF, et al. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. *Breast Cancer Res* 2006;8:R23. [PubMed: 16626501]
38. Liu Y, Hayes DN, Nobel A, Marron JS. Statistical significance of clustering for high dimension low sample size data. *J Am Stat Assoc* 2008;103:1281–1293.
39. Oh DS, Troester MA, Usary J, et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. *J Clin Oncol* 2006;24:1656–1664. [PubMed: 16505416]
40. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. *Proc Natl Acad Sci U S A* 2001;98:5116–5121. [PubMed: 11309499]
41. Dennis G Jr, Sherman BT, Hosack DA, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. *Genome Biol* 2003;4:P3. [PubMed: 12734009]
42. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. *Nat Rev Cancer* 2008;8:11–23. [PubMed: 18097461]
43. Sun H, Ma Z, Li Y, et al. γ -S crystallin gene (CRYGS) mutation causes dominant progressive cortical cataract in humans. *J Med Genet* 2005;42:706–710. [PubMed: 16141006]
44. Moyano JV, Evans JR, Chen F, et al. α B-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. *J Clin Invest* 2006;116:261–270. [PubMed: 16395408]
45. Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. *Cell* 2004;117:927–939. [PubMed: 15210113]
46. Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. *N Engl J Med* 2007;356:217–226. [PubMed: 17229949]
47. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 2007;131:861–872. [PubMed: 18035408]
48. Shipitsin M, Campbell LL, Argani P, et al. Molecular definition of breast tumor heterogeneity. *Cancer Cell* 2007;11:259–273. [PubMed: 17349583]
49. Lien HC, Hsiao YH, Lin YS, et al. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. *Oncogene* 2007;26:7859–7871. [PubMed: 17603561]
50. Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. *J Natl Cancer Inst* 2008;100:672–679. [PubMed: 18445819]
51. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell* 2008;133:704–715. [PubMed: 18485877]
52. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. *Nat Rev Drug Discov* 2005;4:988–1004. [PubMed: 16341064]
53. Hayes MJ, Thomas D, Emmons A, Giordano TJ, Kleer CG. Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast. *Clin Cancer Res* 2008;14:4038–4044. [PubMed: 18593979]




Figure 1. Gene copy number changes. Gains and losses in all common breast cancers (including luminal, *HER-2*-amplified, and basal-like cancers) and basal-like cancers alone versus metaplastic breast tumors were determined. Chromosomes are subdivided into arms and ordered from left to right, beginning with 1p, 1q and ending with X.




Figure 2. Functional proteomics of MBC. Comparative expression of seven core PI3K/AKT pathway phosphoproteins in 383 hormone receptor-positive (*HR*), 142 HER-2-positive (*HER*), and 168 triple-negative (*TN*) breast tumors and 16 MBCs was determined. *GSK3*, glycogen synthase kinase 3; *XpY*, phosphorylation of protein X at amino acid(s) Y.




Figure 3.

Expression of claudin-low and stem cell markers in breast cancer subgroups. Using data from transcriptional profiling, metaplastic (*Metap*) and claudin-low tumors express low levels of claudins CLDN3, CLDN4, and CLDN7 of CDH1 (E-cadherin) and high CD44/CD24 and CD29/CD24 ratios. *P* values (ANOVA). *P* values for the metaplastic-basal comparison of stem cell markers were 0.41 (BMI1), 0.19 (CD44), 0.004 (CD29), 0.00009 (CD24), 0.00006 (CD44/CD24 ratio), and 0.00007 (CD29/CD24 ratio).




Figure 4.

A CD44⁺/CD24^{-/low} “tumorigenic” gene signature is enriched in human breast tumors of the “claudin-low” and metaplastic (MBC) subtypes. The correlation shown is between the “tumorigenic” signature pattern (Creighton and colleagues, submitted for publication; using “1” and “-1,” for up and down genes, respectively) and each MBC as well as each tumor in the gene expression profile dataset by Herschkowitz and colleagues (9). R values above red dotted line are significant ($P < 0.00001$).

Table 1
Frequency of mutations in the *PIK3CA*, *AKT1/2/3*, *PTEN*, and *KRAS* genes in human breast cancers

Tumor subtype	<i>PIK3CA</i> catalytic domain (%)	<i>PIK3CA</i> other (%)	<i>PIK3CA</i> total (%)	<i>PTEN</i> (%)	<i>AKT1</i> E17K (%)	<i>AKT2/3</i> E17K (%)	<i>KRAS</i> (%)
All human breast tumors, excluding metaplastic and claudin-low cancers	73/547 (13.3)	44/547 (8.0)	117/547 (21.4)	2/88 (2.3)	6/418 (1.4)	0/418 (0)	0/418 (0)
Human breast HR+	48/232 (20.7)	32/232 (13.8)	80/232 (34.5)	2/58 (3.4)	6/232 (2.6)	0/232 (0)	0/232 (0)
Human breast HER-2+	13/75 (17.3)	4/75 (5.3)	17/75 (22.7)	0/10 (0)	0/75 (0)	0/75 (0)	0/75 (0)
Human breast TN	12/240 (5.0)	8/240 (3.3)	20/240 (8.3)	0/20 (0)	0/111 (0)	0/111 (0)	0/111 (0)
Human breast claudin-low	0/14 (0)	0/14 (0)	0/14 (0)	–	0/14 (0)	0/14 (0)	0/14 (0)
Human breast metaplastic	4/19 (21.1)	5/19 (26.3)	9/19 (47.4)	1/19 (5.3)	0/19 (0)	0/19 (0)	1/19 (5.3)

NOTE: *PIK3CA*, *AKT1/2/3*, and *PTEN* mutation frequency in hormone receptor–positive (HR+), HER-2–positive, and triple-negative (TN) cancers, used herein as a comparator for metaplastic and claudin–low tumors, has been published (12).